High-resolution separation of amyloid β-peptides: Structural variants present in Alzheimer's disease amyloid

Journal of Neurochemistry

Volumn 67, Issue 1, 1996, Pages 294-301

  Näslund, Jan ^a   Karlström, Anders R ^b   Tjernberg, Lars O ^a   Schierhorn, Angelika ^c   Terenius, Lars ^a   Nordstedt, Christer ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Pharmacia & Upjohn AB   (Sweden)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Alzheimer's disease; Amyloid peptide; Posttranslational modifications; Reverse phase liquid chromatography

Indexed keywords

AMYLOID BETA PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CASE REPORT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN ISOLATION; PROTEIN PROCESSING; PROTEIN PURIFICATION; REVERSED PHASE LIQUID CHROMATOGRAPHY;

EID: 0029889248     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1996.67010294.x     Document Type: Article

References (36)

1. Burdick D., Soreghan B., Kwon M., Kosmoski J., Knauer M., Henschen A., Yates J., Cotman C., and Glabe C. (1992) Assembly and aggregation properties of synthetic Alzheimer's A4/β amyloid peptide analogs. J. Biol. Chem. 267, 546-554.
2. Busciglio J., Gabuzda D. H., Matsudaira P., and Yankner B. A. (1993) Generation of β-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc. Natl. Acad. Sci. USA 90, 2092-2096.
3. Fabian H., Szendrei G. I., Mantsch H. H., Greenberg B. D., and Ötvös L. Jr. (1994) Synthetic post-translationally modified human Aβ peptide exhibits a markedly increased tendency to form β-pleated sheets in vitro. Eur. J. Biochem. 221, 959-964.
4. Glenner G. G. and Wong C. W. (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885-890.
5. Haass C. and Selkoe D. J. (1993) Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide. Cell 75, 1039-1042.
6. Haass C., Schlossmacher M. G., Hung A. Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B. L., Lieberburg I., Koo E. H., Schenk D., Teplow D. B., and Selkoe D. J. (1992) Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 359, 322-325.
7. Haass C., Hung A. Y., Selkoe D. J., and Teplow D. B. (1994) Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid β-protein precursor. J. Biol. Chem. 269, 17741-17748.
8. Harigaya Y., Shoji M., Kawarabayashi T., Kanai M., Nakamura T., Iizuka T., Igeta Y., Saido T. C., Sahara N., Mori H., and Hirai S. (1995) Modified amyloid β protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease. Biochem. Biophys. Res. Commun. 211, 1015-1022.
9. Hilbich C., Kisters-Woike B., Reed J., Masters C. L., and Beyreuther K. (1991) Aggregation and secondary structure of synthetic amyloid βA4 peptides of Alzheimer's disease. J. Mol. Biol. 218, 149-163.
10. Hopp T. P. and Woods K. R. (1981) Prediction of protein antigenic determinants from amino acid sequences. Proc. Natl. Acad. Sci. USA 78, 3824-3828.
11. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., and Ihara Y. (1994) Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). Neuron 13, 45-53.
12. Jarrett J. T., Berger E. P., and Lansbury P. T. Jr. (1993) The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32, 4693-4697.
13. Kametani F., Tanaka K., Tokuda T., and Allsop D. (1995) The immunoreactive profile at the N-terminal region of Aβ 1-39/ 40 but not Aβ 1-42 changes with transition from monomer/ dimer to further peptide aggregates. Brain Res. 703, 237-241.
14. Kim K. S., Miller D. L., Sapienza V. J., Chen C.-M. J., Bai C., Grundke-Iqbal I., Currie J. R., and Wisniewski H. M. (1988) Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. Neurosci. Res. Commun. 2, 121-130.
15. Kim K. S., Wen G. Y., Bancher C., Chen C. J. M., Sapienza V. J., Hong H., and Wisniewski H. M. (1990) Detection and quantitation of amyloid β-peptide with 2 monoclonal antibodies. Neurosci. Res. Commun. 7, 113-122.
16. Masters C. L., Simms G., Weinman N. A., Multhaup G., McDonald B. L., and Beyreuther K. (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad Sci. USA 82, 4245-4249.
17. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E. M. (1984) Clinical diagnosis of Alzheimer's disease. Neurology 34, 939-944.
18. Miller D. L., Papayannopoulos I. A., Styles J., Bobin S. A., Lin Y. Y., Biemann K., and Iqbal K. (1993) Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch. Biochem. Biophys. 301, 41-52.
19. Mori H., Takio K., Ogawara M., and Selkoe D. J. (1992) Mass spectrometry of purified amyloid β protein in Alzheimer's disease. J. Biol. Chem. 267, 17082-17086.
20. Näslund J., Schierhorn A., Hellman U., Lannfelt L., Roses A. D., Tjernberg L. O., Silberring J., Gandy S. E., Winblad B., Greengard P., Nordstedt C., and Terenius L. (1994a) Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging. Proc. Natl. Acad. Sci. USA 91, 8378-8382.
21. Näslund J., Jensen M., Tjernberg L. O., Thyberg J., Terenius L., and Nordstedt C. (1994b) The metabolic pathway generating p3, an Aβ-peptide fragment, is probably non-amyloidogenic. Biochem. Biophys. Res. Commun. 204, 780-787.
22. Näslund J., Thyberg J., Tjernberg L. O., Wernstedt C., Karlström A. R., Bogdanovic N., Gandy S. E., Lannfelt L., Terenius L., and Nordstedt C. (1995) Characterization of stable complexes involving apolipoprotein E and the amyloid β peptide in Alzheimer's disease brain. Neuron 15, 219-228.
23. Nordstedt C., Näslund J., Tjernberg L. O., Karlström A. R., Thyberg J., and Terenius L. (1994) The Alzheimer Aβ peptide develops protease resistance in association with its polymerization into fibrils. J. Biol. Chem. 269, 30773-30776.
24. Pike C. J., Overman M. J., and Cotman C. W. (1995) Amino-terminal deletions enhance aggregation of β-amyloid peptides in vitro. J. Biol. Chem. 270, 23895-23898.
25. Prelli F., Castano E., Glenner G. G., and Frangione B. (1988) Differences between vascular and plaque core amyloid in Alzheimer's disease. J. Neurochem. 51, 648-651.
26. Roher A. E., Lowenson J. D., Clarke S., Wolkow C., Wang R., Cotter R. J., Reardon I. M., Zürcher-Neely H. A., Heinrikson R. L., Ball M. J., and Greenberg B. D. (1993a) Structural alterations in the peptide backbone of β-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J. Biol. Chem. 268, 3072-3083.
27. Roher A. E., Lowenson J. D., Clarke S., Woods A. S., Cotter R. J., Gowing E., and Ball M. J. (1993b) β-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 10836-10840.
28. Saido T. C., Iwatsubo T., Mann D. M., Shimada H., Ihara Y., and Kawashima S. (1995) Dominant and differential deposition of distinct β-amyloid peptide species, AβN3(pE), in senile plaques. Neuron 14, 457-466.
29. Schägger H. and von Jagow G. (1987) Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal. Biochem. 166, 368-379.
30. Selkoe D. J. (1991) The molecular pathology of Alzheimer's disease. Neuron 6, 487-498.
31. Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schlossmacher M., Whaley J., Swindlehurst C., McCormack R., Wolfert R., Selkoe D. J , Lieberburg I., and Schenk D. B. (1992) Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids. Nature 359, 325-327.
32. Shapira R., Austin G. E., and Mirra S. S. (1988) Neuritic plaque amyloid in Alzheimer's disease is highly racemized. J. Neurochem. 50, 69-74.
33. Smith M. A., Taneda S., Richey P. L., Miyata S., Yan S.-D., Stern D., Sayre L. M., Monnier V. M., and Perry G. (1994) Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc. Natl. Acad. Sci. USA 91, 5710-5714.
34. Tomiyama T., Asano S., Furiya Y., Shirasawa T., Endo N., and Mori H. (1994) Racemization of Asp23 residue affects the aggregation properties of Alzheimer amyloid β protein analogues. J. Biol. Chem. 269, 10205-10208.
35. Vigo-Pelfrey C., Lee D., Keim P., Lieberburg I., and Schenk D. B. (1993) Characterization of β-amyloid peptide from human cerebrospinal fluid. J. Neurochem. 61, 1965-1968.
36. Vitek M. P., Bhattacharya K., Glendening J. M., Stopa E., Vlassara H., Bucala R., Manogue K., and Cerami A. (1994) Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. USA 91, 4766-4770.